Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | DRD1 | P21728 | 5/20 | 0.41 |
| ▸ | DRD5 | P21918 | 5/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719753 | 0.81 | HTR2C (0.42) | PDGFRBPDGFRADRD2 | |
| SCHEMBL718246 | 0.80 | DRD2 (0.46) | MAOAMAOBSLC6A4DRD2DRD1 | |
| SCHEMBL720478 | 0.77 | DRD1 (0.45) | MAOAMAOBSLC6A4DRD2DRD1 | |
| SCHEMBL719961 | 0.77 | ALDH1A1 (0.55) | MAOAMAOBSLC6A4DRD2DRD1 | |
| SCHEMBL14437924 | 0.73 | PDGFRB (0.63) | PDGFRBPDGFRA | |
| SCHEMBL717813 | 0.73 | MEN1 (0.52) | MAOAMAOBSLC6A4DRD2DRD1 | |
| SCHEMBL13094745 | 0.72 | MAOA (0.57) | MAOAMAOBSLC6A4DRD2DRD1 | |
| Trifluoroacetic Acid SCHEMBL719514 | 0.70 | PKM (0.38) | PDGFRBPDGFRADRD2HRH4 | |
| SCHEMBL22549016 | 0.69 | PDGFRB (0.43) | PDGFRBPDGFRA | |
| SCHEMBL18034941 | 0.69 | MAOA (0.38) | MAOAMAOBSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053168-A1 | FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2012-03-01 | — | — | US | claimed |
| WO-2010096384-A2 | FUSED BENZAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2010-08-26 | — | — | WO | claimed |
| US-20120053168-A1 | FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2010096384-A2 | FUSED BENZAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053168-A1 | FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA2, CHRNA5, CHRNA10 | MAOA 584/4885MAOB 543/4885SLC6A4 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.